Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.
Inoculation of rabbits and mice with a vaccinia-rabies glycoprotein recombinant (V-RG) virus resulted in rapid induction of high concentrations of rabies virus-neutralizing antibodies and protection from severe intracerebral challenge with several strains of rabies virus. Protection from virus challenge also was achieved against the rabies-related Duvenhage virus but not against the Mokola virus. Effective immunization by V-RG depended on the expression of a rabies glycoprotein that registered proline rather than leucine as the eighth amino acid from its NH2 terminus (V-RGpro8). A minimum dose required for effective immunization of mice was 10(4) plaque-forming units of V-RGpro8 virus. beta-propiolactone-inactivated preparations of V-RGpro8 virus also induced high levels of rabies virus-neutralizing antibody and protected mice against intracerebral challenge with street rabies virus. V-RGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabies virus.
D000818:Animals; D004274:DNA, Recombinant; D005260:Female; D005814:Genes, Viral; D005822:Genetic Vectors; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology*; D007111:Immunity, Cellular; D007156:Immunologic Memory; D051379:Mice; D011819:Rabies Vaccines / Q000276:immunology*; D011820:Rabies virus / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics; D014764:Viral Proteins / Q000235:genetics / Q000276:immunology
D004274:DNA, Recombinant; D006023:Glycoproteins; D011819:Rabies Vaccines; D014764:Viral Proteins